Bepranemab
CAS No. 2244960-75-4
Bepranemab( —— )
Catalog No. M36774 CAS No. 2244960-75-4
Bepranemab (UCB 0107), a humanized full-length IgG4 monoclonal antibody, targets the central tau epitope (amino acids 235-250) and is utilized in Alzheimer’s disease (AD) research .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBepranemab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBepranemab (UCB 0107), a humanized full-length IgG4 monoclonal antibody, targets the central tau epitope (amino acids 235-250) and is utilized in Alzheimer’s disease (AD) research .
-
DescriptionBepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2244960-75-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.
molnova catalog
related products
-
Protein Kinase G Sub...
Protein Kinase G Substrate; G-Subtide
-
Halopemide
Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.
-
AH 6696
AH 6696 is a biochemical.
Cart
sales@molnova.com